- For Quality Assurance: attention now remains on the status and evidence behind NerPharMa’s GMP remediation.
- For Regulatory Affairs: the next submission depends on resolving the manufacturing-related requirements identified in the CRL. Meanwhile,
- Manufacturing and Validation teams: face a clear operational task: producing the additional consecutive commercial-scale batch data requested by FDA.
FDA’s Dasynoc CRL Puts Manufacturing Readiness at the Center
FDA’s CRL focuses on unresolved GMP observations at NerPharMa and the need for additional consecutive commercial-scale batch data. Xspray said FDA raised no new concerns about Dasynoc’s clinical data, bioequivalence, or stability. NerPharMa says remediation is complete, but FDA has not yet decided whether the site will require reinspection.
Xspray Moves Consecutive Commercial Batches to the Top of Its 2026 Resubmission Plan
Xspray will prioritize additional commercial-scale batches to generate the data requested by FDA. The company plans to resubmit the Dasynoc NDA during 2026, which could lead to a new PDUFA date. CEO Blake Leitch said the remaining uncertainty centers on NerPharMa’s GMP remediation and the required consecutive manufacturing-run data.
Why the Dasynoc CRL Is a Warning for Pharma Manufacturers and Quality Teams
The case gives pharmaceutical quality teams a practical example of how third-party manufacturing status can remain directly connected to an active marketing application. Even when other parts of an application are not questioned, outstanding manufacturing requirements can still determine what evidence must be completed before another regulatory review can begin.
Specialist poll: If your NDA depended on the same two unresolved areas, which would create the greater resubmission-readiness challenge: A) demonstrating satisfactory manufacturing-site remediation or B) generating consecutive commercial-scale batch evidence?
What QA, Validation, and Regulatory Teams Should Learn From the Dasynoc CRL
The case shows why manufacturing remediation, validation evidence, and regulatory strategy must remain aligned when an approval depends on a third-party site.
| Role | Impact / Risk | Immediate Action | Evidence to Review |
|---|---|---|---|
|
Quality Assurance |
NerPharMa’s GMP remediation remains relevant to FDA assessment |
Confirm remediation evidence is complete and traceable |
CAPA records, remediation documentation, quality records |
|
Regulatory Affairs |
Resubmission depends on addressing manufacturing-related CRL requirements |
Map each FDA request to the NDA resubmission package |
CRL requirements, updated submission sections, supporting data |
|
Validation |
Additional consecutive commercial-scale batch data are required |
Review whether production and validation evidence supports resubmission |
Process validation data, batch records, manufacturing results |
|
Manufacturing |
Additional commercial-scale production runs must be prioritized |
Execute and document the required consecutive batches |
Executed batch records and production data |
|
Quality Leadership |
Third-party manufacturing readiness remains a regulatory dependency |
Maintain oversight of remediation and resubmission readiness |
Supplier oversight records, remediation status, management review |
What Happens Next for Dasynoc After the FDA CRL?
The next major signal will be FDA’s decision on whether NerPharMa requires reinspection. After that, attention will move to completion of the requested consecutive commercial-scale batch data and Xspray’s planned NDA resubmission during 2026. A new PDUFA date would then provide the next defined milestone in the Dasynoc review.
Strengthening GMP Manufacturing and Validation Readiness After Regulatory Findings
Zamann Pharma’s Qualification and Validation for GMP-Regulated Systems service supports pharmaceutical teams with qualification and validation activities, including process validation across the lifecycle. Teams reviewing manufacturing and validation readiness after regulatory observations can explore this support where additional hands-on expertise is needed.
Source: Marketscreener.Com